Now that a new standard of care has been established in frontline mesothelioma, clinical trials are needed to evaluate optimal sequencing with checkpoint inhibitors in the salvage setting and determine whether biomarkers of response to immunotherapy could further tailor treatment to individual patients, said Anne S. Tsao, MD, during a virtual … [Read more...]
Study finds drug beneficial for shrinking mesothelioma tumors
A drug that is designed to boost the immune system against mesothelioma, when combined with immunotherapy, was found to be beneficial in a small study involving ten patients. The results, which appeared July 1, 2020, in Science Translational Medicine, suggest that the drug LMB-100 could prolong the life of some patients with advanced … [Read more...]